Skip to content
Open access

Guideline-directed medical therapy and outcomes in frail patients with HFrEF and low blood pressure : insights from the JROADHF-NEXT

Oct 2026 · European Heart Journal · 0 citations

TL;DR

In frail patients with HFrEF and low BP, contemporary GDMT was associated with improved clinical outcomes.

Abstract

Low blood pressure (BP) and frailty are major barriers to guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF). Data on GDMT utilization and its prognostic impact in frail patients with HFrEF and low BP remain limited. To investigate prescription patterns of GDMT and assess whether contemporary GDMT is associated with clinical outcomes in frail patients with HFrEF and low BP. From the JROADHF-NEXT database, we analyzed patients hospitalized for acute HF with left ventricular ejection fraction <40%, discharge systolic BP ≤100 mmHg, and Clinical Frailty Scale (CFS) score 4–7. Patients were categorized into three groups according to discharge GDMT: group 1, ACE-I/ARB/ARNI + β-blocker + MRA + SGLT2-I; group 2, ACE-I/ARB/ARNI + β-blocker; and group 3, others. The primary outcome was all-cause mortality, and the secondary outcome was cardiovascular death. A total of 382 patients were included (mean age 69 ± 14 years; 68% male; median CFS 4 [IQR 4–5]). Mean discharge BP was 90 ± 7 mmHg and increased to 107 ± 21 mmHg at 12 months. At discharge, ACEI/ARB/ARNI, β-blockers, MRAs, and SGLT2-Is were prescribed in 78%, 91%, 79%, and 26% of patients, respectively, and continued in 78%, 89%, 73%, and 34% at 12 months. The contemporary GDMT (Group 1) was prescribed in 69 patients (18%), whereas conventional GDMT (Group 2) was prescribed in 194 patients (51%). During a median follow-up of 1.95 years, 100 patients (26%) died. Compared with group 1, adjusted HRs for all-cause mortality were 1.67 (95% CI 0.82–3.44, p=0.159) in group 2 and 2.63 (95% CI 1.28–5.43, p=0.009) in group 3; for cardiovascular death, the corresponding HRs were 2.00 (95% CI 0.73–5.50, p=0.175) and 3.95 (95% CI 1.47–10.6, p=0.007), respectively. In frail patients with HFrEF and low BP, contemporary GDMT was associated with improved clinical outcomes.

Read PDF

Similar papers

Open access Oct 2026

Impact of higher comorbidity burden on guideline-directed medical therapy in patients with heart failure with reduced ejection fraction

Patients with a higher comorbidity burden less often used quadruple therapy and had a worse prognosis, as well as its association with clinical outcomes, according to a prespecified subanalysis of the TITRATE-HF registry.

J. J. N. Krabbe, M. I. Wilde, A. Mosterd et al. · 0 citations
Oct 2026

Insights from the therapy of heart failure at discharge (TESCODI) study: how far from full appropriateness are we in older and frail patients?

BACKGROUND Guideline-directed medical therapy (GDMT) for heart failure (HF) is often underused in older frail patients. We assessed discharge prescribing and determinants of low-prescription across Internal Medicine and Geriatrics wards in Tuscany, Italy. METHODS This prospective, multicenter, observational study inc...

Francesco Cei, Antonella Al Refaie, S. Dolenti et al. · 0 citations
Review Oct 2026

Multidisciplinary cardiac case conference overcomes therapeutic inertia in heart failure: achieving guideline-directed therapy in high-risk populations

The two-to-five-month HF duration group showed greatest recovery, supporting structured early intervention, in keeping with the STRONG-HF trial, and patients with "stable" disease often overlooked for intensification showed greatest recovery.

N. Sowden, V. Bryce, K. Goodhew et al. · 0 citations
Open access Oct 2026

Temporal trends and prognostic impact of comprehensive guideline-directed medical therapy in HFrEF: a 1-year follow-up from the KorHF III registry

Comprehensive guideline-directed medical therapy (GDMT) improves survival in heart failure with reduced ejection fraction (HFrEF). However, real-world implementation and its longitudinal impact on outcomes remain incompletely characterized. This study evaluated temporal trends in GDMT implementation and th...

S. Kim, B. Yoo, J. Son · 0 citations
Open access Oct 2026

Association between up-titration of guideline-directed medical therapy and clinical outcomes in patients with chronic heart failure with reduced ejection fraction

In patients with HFrEF, up-titration of GDMT was independently associated with favourable clinical outcomes and LVRR, and the GDMT score could facilitate optimisation of GDMT even in patients with chronic HFrEF.

Y. Agata, T. Nagai, T. Tamura et al. · 0 citations
Open access Nov 2026

Clinical and Social Determinants of Guideline-Directed Medical Therapy Optimization in Heart Failure with Reduced Ejection Fraction

In patients with HFrEF referred to Cardiology in a safety net tertiary care center, higher utilization of GDMT at 90 days was achieved in those who have diabetes mellitus, more frequent medical appointments, or lower serum eGFR, emphasizing the role of healthcare access and utilization.

M. Nelson, M. Kwon, K. Driscoll et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.